전태연 (Tae-Yeon Jeon)

Chief Executive Officer / Representative Director

Therapeutic Areas

Drug	Indication	Phase
ALT-B4	Subcutaneous Drug Delivery Facilitator	Commercial
Keytruda SC	Various Cancers (SC Formulation)	Pre-registration
NexP™ Obesity Treatment	Obesity	Preclinical
NexMab™ ADC Candidates	Oncology	Discovery
Biogen Hybrozyme™ Program 1	Undisclosed	Discovery
Biogen Hybrozyme™ Program 2	Undisclosed	Discovery